retatrutide clinical trial weight loss data 🚨 BREAKING: Shows “Bariatric-Level” in Phase 3 New Phase 3 TRIUMPH-1 show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Everyone's talking about Retatrutide… but

This influx of Ca 2+ then triggers exocytosis of insulin-containing granules

The best available evidence suggests retatrutide can produce major fat-mass reduction and that lean-mass loss, relative to total weight loss, appears similar to other obesity therapies rather than disproportionately worse

Yagi K, Imamura T, Tada H, Chujo D, Liu J, Shima Y, et al

Research suggests GIP agonism also amplifies the weight loss effects of GLP-1, which explains why dual-agonists like tirzepatide outperform single-agonists like semaglutide

According to the FDA and Eli Lilly, you should not take Foundayo if you (1, 3): Have a personal or family history of medullary thyroid carcinoma Have Multiple Endocrine Neoplasia syndrome type 2 Are currently taking another GLP-1 receptor agonist medication Foundayo has not been studied in children (3)

Everyone's experience is different, but in our clinical studies, women showed results in 3-6 months